Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelareorep - Adlai Nortye/Oncolytics Biotech

Drug Profile

Pelareorep - Adlai Nortye/Oncolytics Biotech

Alternative Names: AN1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus

Latest Information Update: 10 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolytics Biotech
  • Developer Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Glioblastoma; Multiple myeloma
  • Preclinical Liver cancer; Viral hepatitis
  • No development reported Solid tumours

Most Recent Events

  • 31 Oct 2019 Adlai Nortye plans a phase III registrational trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China
  • 22 Oct 2019 Oncolytics Biotech and PrECOG agree to collaborate for the phase II BRACELET-1 trial for Breast cancer in USA
  • 22 Oct 2019 Oncolytics Biotech plans a phase III registrational study for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top